Generation and mucosal transmissibility of emtricitabine- and tenofovir-resistant SHIV162P3 mutants in macaques

Virology

Volumn 412, Issue 2, 2011, Pages 435-440

  Cong, Mian er ^a   Youngpairoj, Ae S ^a   Aung, Wutyi ^a   Sharma, Sunita ^a   Mitchell, James ^a   Dobard, Charles ^a   Heneine, Walid ^a   Garcia Lerma, J Gerardo ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

HIV 1 drug resistance; Mucosal transmissibility; Pre exposure prophylaxis

Indexed keywords

EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; TENOFOVIR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MACACA; MUCOSA; NONHUMAN; PERITONITIS; PRIORITY JOURNAL; RECTUM DISEASE; VAGINITIS; VIRION; VIRUS INFECTIVITY; VIRUS PARTICLE; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS TRANSMISSION;

ADENINE; ANIMALS; ANTI-HIV AGENTS; DEOXYCYTIDINE; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, VIRAL; HIV; HUMANS; MACACA; MUTATION; PHOSPHONIC ACIDS; RECOMBINATION, GENETIC; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS CULTIVATION;

HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA;

EID: 79952631079     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2011.01.038     Document Type: Article

References (42)

1. Abdool Karim Q., Abdool Karim S., Frohlich J., Grobler A., Baxter C., Mansoor L., Kharsany A., Sibeko S., Mlisana K., Omar Z., Gengiah T., Maarschalk S., Arulappan N., Mlotshwa M., Morris L., Taylor D. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010, 329:1168-1174. Caprisa 004 Trial Group.
2. Brenner B.G., Routy J.P., Petrella M., Moisi D., Oliveira M., Detorio M., Spira B., Essabag V., Conway B., Lalonde R., Sekaly R.P., Wainberg M.A. Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection. J. Virol. 2002, 76:1753-1761.
3. Cane P.A. Stability of transmitted drug-resistant HIV-1 species. Curr. Op Infect Dis 2005, 18:537-542.
4. Cohen M.S., Gay C., Kashuba A.D., Blower S., Paxton L. Narrative review: antiretroviral therapy to prevent the sexual transmission of HIV-1. Ann. Intern. Med. 2007, 146:591-601.
5. Cong M., Heneine W., García-Lerma J.G. The fitness cost of mutations associated with human immunodeficiency virus type 1 drug resistance is modulated by mutational interactions. J. Virol. 2007, 81:3037-3041.
6. Deval J., Navarro J.M., Selmi B., Courcambeck J., Boretto J., Halfon P., Garrido-Urbani S., Sire J., Canard B. A loss of viral replicative capacity correlates with altered DNA polymerization kinetics by the human immunodeficiency virus reverse transcriptase bearing the K65R and L74V dideoxynucleoside resistance substitutions. J. Biol. Chem. 2004, 279:25489-25496.
7. Deval J., White K.L., Miller M.D., et al. Mechanistic basis for reduced viral and enzymatic fitness of HIV-1 reverse transcriptase containing both K65R and M184V mutations. J. Biol. Chem. 2004, 279:509-516.
8. García-Lerma J.G., Cong M., Mitchell J., Youngpairoj A.S., Zheng Q., Masciotra S., Martin A., Kuklenyik Z., Holder A., Lipscomnb J., Pau C., Barr J.R., Hanson D.L., Otten R.A., Paxton L., Folks T.M., Heneine W. Intermittent prophylaxis with oral truvada protects macques form rectal SHIV infection. Sci. Transl. Med. 2010, 2:14ra4.
9. García-Lerma J.G., Gerrish P.J., Wright A.J., Qari S.H., Heneine W. Evidence of a role for the Q151L mutation and the viral background in development of multiple dideoxynucleoside resistant HIV-1. J. Virol. 2000, 74:9339-9346.
10. García-Lerma J.G., Heneine W. Analysis of HIV-1 reverse transcriptase activity in plasma: a new tool for the detection of viral variants, virus load measurement and phenotypic drug resistance testing. AIDS Rev. 1999, 1:80-88.
11. García-Lerma J.G., Nidtha S., Heneine W. Susceptibility of the human T-cell leukemia virus type 1 to reverse transcriptase inhibitors: evidence of high level resistance to lamivudine. J. Infect. Dis. 2001, 184:507-510.
12. García-Lerma J.G., Otten R.A., Qari S.H., Jackson E., Cong M., Masciotra S., Luo W., Kim C., Adams D.R., Monsour M., Lipscomb J., Johnson J.A., Delinsky D., Schinazi R.F., Janssen R., Folks T.M., Heneine W. Prevention of rectal SHIV transmission in macaques by Daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med. 2008, 5:e28.
13. García-Lerma J.G., Paxton L., Kilmarx P., Heneine W. Oral pre-exposure prophylaxis for HIV prevention. Trends Pharmacol. Sci. 2010, 31:74-81.
14. Geretti A.M. Epidemiology of antiretroviral drug resistance in drug-naïve persons. Curr. Opin. Infect. Dis. 2007, 20:22-32.
15. Grant R.M., Buchbinder S., Cates W., Clarke E., Coates T., Cohen M.S., Delaney M., Flores G., Goicochea P., Gonsalves G., Harrington M., Lama J.R., MacQueen K.M., Moore J.P., Peterson L., Sanchez J., Thompson M., Wainberg M.A. Promote HIV chemoprophylaxis research, don't prevent it. Science 2005, 309:2170-2171.
16. Grant R.M., Lama J.R., Anderson P.L., McMahan V., Liu A.Y., Vargas L., Goicochea P., Casapía M., Guanira-Carranza J.V., Ramirez-Cardich M.E., Montoya-Herrera O., Fernández T., Veloso V.G., Buchbinder S.P., Chariyalertsak S., Schechter M., Bekker L.G., Mayer K.H., Kallás E.G., Amico K.R., Mulligan K., Bushman L.R., Hance R.J., Ganoza C., Defechereux P., Postle B., Wang F., McConnell J.J., Zheng J.H., Lee J., Rooney J.F., Jaffe H.S., Martinez A.I., Burns D.N., Glidden D.V. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N. Engl. J. Med. 2010, 363:2587-2599. Team., t. i. S.
17. Harouse J.M., Gettie A., Eshetu T., Tan R.C., Bohm R., Blanchard J., Baskin G., Cheng-Mayer C. Mucosal transmission and induction of simian AIDS by CCR5-specific simian/human immunodeficiency virus SHIV(SF162P3). J. Virol. 2001, 75:1990-1995.
18. Harouse J.M., Gettie A., Tan R.C., Blanchard J., Cheng-Mayer C. Distinct pathogenic sequela in rhesus macaques infected with CCR5 or CXCR4 utilizing SHIVs. Science 1999, 284:816-819.
19. Hsu M., Ho S., Balfe P., Gettie A., Harouse J., Blanchard J., Cheng-Mayer C. A CCR5-tropic simian-HIV molecular clone capable of inducing AIDS in rhesus macaques. J. Acquir. Immune Defic. Syndr. 2005, 40:383-387.
20. Japour A.J., Mayers D.L., Johnson V.A., Kuritzkes D.R., Beckett L.A., Arduino J.M., Lane J., Black R.J., Reichelderfer P.S., D'Aquila R.T., et al. Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. Antimicrob. Agents Chemother. 1993, 37:1095-1101.
21. Kim C., Adams D., Bashirian S., Butera S., Folks T., Otten R. Repetitive exposures with simian/human immunodeficiency viruses: strategy to study HIV pre-clinical interventions in non-human primates. J. Med. Primatol. 2006, 35:210-216.
22. Leigh Brown A.J., Frost S.D., Mathews W.C., et al. Transmission fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral-treated population. J. Infect. Dis. 2003, 187:683-686.
23. Luciw P.A., Pratt-Lowe E., Shaw K.E., Levy J.A., Cheng-Mayer C. Persistent infection of rhesus macaques with T-cell-line-tropic and macrophage-tropic clones of simian/human immunodeficiency viruses (SHIV). Proc. Natl Acad. Sci. USA 1995, 92:7490-7494.
24. Martinez-Picado J., Savara A.V., Sutton L., D'Aquila R.T. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1. J. Virol. 1999, 73:3744-3752.
25. Miller M.D. K65R, TAMs, and tenofovir. AIDS Rev. 2004, 6:22-33.
26. Murray J.M. Changing transmission fitness of drug-resistant human immunodeficiency virus against a background of evolving antiretroviral therapy. J. Infect. Dis. 2003, 188:1258.
27. Myers G.J., Berzofsky A., Korber B., Smith R.F., Pavlakis G.N. A compilation and analysis of nucleic acid and amino acid sequences. Los Alamos National Laboratory, Los Alamos, N.Mex. Human Retroviruses and AIDS 1991.
28. Otten R.A., Adams D.R., Kim C.N., Jackson E., Pullium J.K., Lee K., Grohskopf L.A., Monsour M., Butera S., TM F. Multiple vaginal exposures to low doses of R5 simian-human immunodeficiency virus: strategy to study HIV preclinical interventions in nonhuman primates. J. Infect. Dis. 2005, 19:164-173.
29. Parikh U., Dobard C., Sharma S., Cong M., Jia H., Martin A., Pau C., Hanson D., Guenthner P., Smith J., Kersh E., García-Lerma J., Novembre F., Otten R., Folks T., Heneine W. Complete protection from repeated vaginal SHIV exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine. J. Virol. 2009, 83:10358-10365.
30. Schinazi R.F., Lloyd R.M., Nguyen M.H., Cannon D.L., McMillan A., Ilksoy N., Chu C.K., Liotta D.C., Bazmi H.Z., Mellors W. Characterization of human immunodeficiency viruses resistant to oxatiolate-cytosine nucleosides. Antimicrob. Agents Chemother. 1993, 37:875-881.
31. Schuurman R., Nijhuis M., van Leeuwen R., Schipper P., de Jong D., Collis P., Danner S., Mulder J., Loveday C., Christopherson C., Kwok S., Sninsky J., Boucher C. Rapid changes in HIV-1 RNA load and appearance of drug-resistant virus population in persons treated with lamivudine (3TC). J. Infect. Dis. 1995, 171:1411-1419.
32. Shafer R., Schapiro J. HIV-1 drug resistance mutations: an updated framework for the second decade of HAART. AIDS Rev. 2008, 10:67-84.
33. Subbarao S., Otten R.A., Ramos A., Kim C., Jackson E., Monsour M., Adams D.R., Bashirian S., Johnson J., Soriano V., Rendon A., Hudgens M.G., Butera S., Janssen R., Paxton L., Greenberg A.E., M.F.T. Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges. J. Infect. Dis. 2006, 194:904-911.
34. van Rompay K.K., Cherrington J.M., Marthas M.L., Berardi C.J., Mulato A.S., Spinner A., Tarara R.P., Canfield D.R., Telm S., Bischofberger N., Pedersen N.C. 9-[2-(Phosphonomethoxy)propyl]adenine therapy of established simian immunodeficiency virus infection in infant rhesus macaques. Antimicrob. Agents Chemother. 1996, 40:2586-2591.
35. van Rompay K.K., Matthews T.B., Higgins J., Canfield D.R., Tarara R.P., Wainberg M.A., Schinazi R.F., Pedersen N.C., North T.W. Virulence and reduced fitness of SIV with the M184V mutation in reverse transcriptase. J. Virol. 2002, 76:6083-6092.
36. Vishwanathan S.A., Guenthner P., Lin C., McNicholl J., Dobard C., Srinivasan P., Otten R., Heneine W., Hendry M., Kersh E. 2010.
37. Wainberg M., Salomon H., Gu Z., Montaner J., Cooley T., MaCaffrey R., Ruedy J., Hirst H., Cammack N., Cameron J., Nicholson W. Development of HIV-1 resistance to (-) 2′-deoxy-3′-thiactytidine in patients with AIDS or advanced AIDS-related complex. AIDS 1995, 9:351-357.
38. Wainberg M.A., Hsu M., Gu Z., Borkow G., Parniak M.A. Effectiveness of 3TC in HIV clinical trials may be due in part to the M184V substitution in 3TC-resistant HIV-1 reverse transcriptase. AIDS 1996, 10:S3-S10.
39. Wainberg M.A., Miller M.D., Quan Y., Salomon H., Mulato A.S., Lamy P.D., Margot N.A., Anton K.E., Cherrington J.M. In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA. Antivir. Ther. 1999, 4:87-94.
40. Wei X., Decker J., Liu H., Zhang Z., Arani R., Kilby J., Saag M.S., Wu X., Shaw G., Kappes J. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 2002, 46:1896-1905.
41. White K.L., Margot N.A., Wrin T., Petropoulos C.J., Miller M.D., Naeger L.K. Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R+M184V and their effects on enzyme function and viral replication capacity. Antimicrob. Agents Chemother. 2002, 46:3437-3446.
42. Wira C.R., Fahey J.V. A new strategy to understand how HIV infects women: identification of a window of vulnerability during the menstrual cycle. AIDS 2008, 22:1909-1917.